← العودة إلى الصفحة الرئيسية
الولايات المتحدة · منصات وبيانات · Yahoo Finance

J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports

نشره Yahoo Finance · الولايات المتحدة منذ 10 س
J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports
Yahoo Finance

ملخص مفصل

Investing.com-- Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial…

Investing.com-- Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.

The deal could involve an upfront cash payment of $2.2 billion and up to $1.2 billion in milestone payments, although discussions could still fall apart, the report said.

Stop chasing stocks after they've already rallied. Find your next investment opportunity with AI stock picks, earnings insights, and market-moving news. Yahoo! Finance readers get an extra 15% off on top of the 55% off Black Friday price. Join today! »

Ollin, backed by Arch Venture Partners and Mubadala Capital, is developing OLN324, a drug targeting wet age-related macular degeneration and diabetic macular oedema, two leading causes of severe vision loss. The treatment is expected to enter late-stage clinical trials.

The acquisition would expand J&J's presence in retinal disease treatments, an area where it has limited exposure despite its contact lens business.

The potential deal comes amid a record year for biotech acquisitions, with 46 companies valued at more than $1 billion sold so far, surpassing the previous annual record of 35, according to investment bank Stifel, the FT reported.

J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports

مطلع المقال، مقتطف من Yahoo Finance. لقراءة المقال كاملًا، افتحه على موقع الناشر.

اقرأ المقال كاملًا على Yahoo Finance سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (finance.yahoo.com)

يستحق القراءة أيضًا